News

The results represent a “historic” moment in cystic fibrosis care.

The pharma giant reported sales of £9.4 billion for the third quarter, with HIV drug sales also supporting profits.

Biogen is set to pay Alkermes $150 million in connection with the approval.

The findings also show that deliveries for women under 20 have more than halved in a decade.

The decision marks the first biologic approved in the European Union for severe chronic rhinosinusitis.

The project will help to accelerate and support the development of nurses and midwives looking to develop a career leading research.

The decision was based on a “low probability to meet main goal of study.”

The decision comes as both drugs, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the areas.

The drug was initially given a NICE nod back in 2016, and cleared by the European regulators back in 2011.

In an initial pilot that used Facebook to promote breast screening, one area saw a 12.9% increase in the take up of screening services.

NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function.

The company will use it to develop its portfolio of instrument-free, point-of-care molecular diagnostic tests.

The approval was based on positive interim results from the Phase III JAVELIN Renal 101 study.

The drug is the first in a new chemical class of antibiotics dubbed “triazaacenaphthylene bacterial topoisomerase inhibitors.”